Volatile substance abuse: a brief report.

A Langa

PubMed · 8334071

Volatile substance abuse: a brief report.

Abstract

Volatile substance abuse (VSA) is on the increase: the practice is widespread among young people and concern has often been expressed about its potential dangers. It is estimated that in the United Kingdom between 3.5-10% of current adolescents have at least experimented with solvents, and up to 1% of the secondary school population are currently abusers. Adequate assessment of each individual case is essential as this will lead to appropriate therapeutic interventions and rational management of associated problems.

Explore related subjects

Administration, Inhalation Adolescent Child Female Household Products Humans Male Prevalence Solvents Substance Abuse Detection Substance-Related Disorders Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

A Langa. Volatile substance abuse: a brief report.. https://pubmed.ncbi.nlm.nih.gov/8334071/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗

PubMed2007

Inhaled corticosteroids for chronic obstructive pulmonary disease: a status report.

Explore the source record for details and available documents.

Administration, Inhalation↗

PubMed2007

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗